BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25837253)

  • 1. Mutation in Osteoactivin Promotes Receptor Activator of NFκB Ligand (RANKL)-mediated Osteoclast Differentiation and Survival but Inhibits Osteoclast Function.
    Abdelmagid SM; Sondag GR; Moussa FM; Belcher JY; Yu B; Stinnett H; Novak K; Mbimba T; Khol M; Hankenson KD; Malcuit C; Safadi FF
    J Biol Chem; 2015 Aug; 290(33):20128-46. PubMed ID: 25837253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation in osteoactivin decreases bone formation in vivo and osteoblast differentiation in vitro.
    Abdelmagid SM; Belcher JY; Moussa FM; Lababidi SL; Sondag GR; Novak KM; Sanyurah AS; Frara NA; Razmpour R; Del Carpio-Cano FE; Safadi FF
    Am J Pathol; 2014 Mar; 184(3):697-713. PubMed ID: 24462663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transgenic Expression of Osteoactivin/gpnmb Enhances Bone Formation In Vivo and Osteoprogenitor Differentiation Ex Vivo.
    Frara N; Abdelmagid SM; Sondag GR; Moussa FM; Yingling VR; Owen TA; Popoff SN; Barbe MF; Safadi FF
    J Cell Physiol; 2016 Jan; 231(1):72-83. PubMed ID: 25899717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoactivin inhibition of osteoclastogenesis is mediated through CD44-ERK signaling.
    Sondag GR; Mbimba TS; Moussa FM; Novak K; Yu B; Jaber FA; Abdelmagid SM; Geldenhuys WJ; Safadi FF
    Exp Mol Med; 2016 Sep; 48(9):e257. PubMed ID: 27585719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors.
    Sugatani T; Alvarez UM; Hruska KA
    J Cell Biochem; 2003 Sep; 90(1):59-67. PubMed ID: 12938156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12.
    Kameda Y; Takahata M; Komatsu M; Mikuni S; Hatakeyama S; Shimizu T; Angata T; Kinjo M; Minami A; Iwasaki N
    J Bone Miner Res; 2013 Dec; 28(12):2463-75. PubMed ID: 23677868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
    Cai X; Xing J; Long CL; Peng Q; Humphrey MB
    J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoactivin is a novel osteoclastic protein and plays a key role in osteoclast differentiation and activity.
    Sheng MH; Wergedal JE; Mohan S; Lau KH
    FEBS Lett; 2008 Apr; 582(10):1451-8. PubMed ID: 18381073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
    Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
    Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
    Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
    Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
    Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
    J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microphthalmia transcription factor regulates the expression of the novel osteoclast factor GPNMB.
    Ripoll VM; Meadows NA; Raggatt LJ; Chang MK; Pettit AR; Cassady AI; Hume DA
    Gene; 2008 Apr; 413(1-2):32-41. PubMed ID: 18313864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation.
    Lee SE; Woo KM; Kim SY; Kim HM; Kwack K; Lee ZH; Kim HH
    Bone; 2002 Jan; 30(1):71-7. PubMed ID: 11792567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dominant negative N-cadherin inhibits osteoclast differentiation by interfering with beta-catenin regulation of RANKL, independent of cell-cell adhesion.
    Shin CS; Her SJ; Kim JA; Kim DH; Kim SW; Kim SY; Kim HS; Park KH; Kim JG; Kitazawa R; Cheng SL; Civitelli R
    J Bone Miner Res; 2005 Dec; 20(12):2200-12. PubMed ID: 16294273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biphasic silica/apatite co-mineralized collagen scaffolds stimulate osteogenesis and inhibit RANKL-mediated osteoclastogenesis.
    Jiao K; Niu LN; Li QH; Chen FM; Zhao W; Li JJ; Chen JH; Cutler CW; Pashley DH; Tay FR
    Acta Biomater; 2015 Jun; 19():23-32. PubMed ID: 25792280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class A Scavenger Receptor Exacerbates Osteoclastogenesis by an Interleukin-6-Mediated Mechanism through ERK and JNK Signaling Pathways.
    Guo S; Ni Y; Ben J; Xia Y; Zhou T; Wang D; Ni J; Bai H; Wang L; Ma J; Chen Q
    Int J Biol Sci; 2016; 12(10):1155-1167. PubMed ID: 27766031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pterostilbene derivative suppresses osteoclastogenesis by regulating RANKL-mediated NFκB and MAPK signaling in RAW264.7 cells.
    Nikhil K; Sharan S; Roy P
    Pharmacol Rep; 2015 Dec; 67(6):1264-72. PubMed ID: 26481551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.